Aurinia Pharma

Q2 FY2026 EarningsQ2 FY26 beat consensus across all key financial metrics, with total revenue of $83.2M exceeding the $80.5M expectation and diluted EPS of $0.28 significantly outperforming the $0.24 mean estimate. LUPKYNIS net product sales grew 19% YoY to $79.4M, while operating cash flow of $52.5M came in well above the ~$44.6M expected for the period. Management reiterated FY2026 revenue guidance of $315M-$325M, which remains in-line with current market trajectories.